News & Updates

Men who regularly consume dairy foods are more likely to develop prostate cancer than those with a lower level of consumption, a prospective cohort study has found.

The anti-PD-L1 antibody avelumab demonstrated clinical activity as first-line treatment for patients with metastatic or locally advanced urothelial carcinoma who were PD-L1-positive and ineligible for cisplatin, according to findings from the ARIES trial presented at EAU 2022.

Patients with bladder cancer suffer from high rates of sexual dysfunction, especially those who have undergone radical treatments, a recent study has found.

The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a drug class mainly used for the management of type 2 diabetes, significantly reduces serum uric acid (SUA) concentration, a recent study has shown.

Men with moderate erectile dysfunction (ED) may benefit from having 12 sessions of low-intensity shock wave therapy (SWT) twice weekly for 6 weeks, with a treatment protocol of 5,000 impulses, 0.0096 mJ/mm2 energy flux density, and 5-Hz frequency, suggests a study.

Adhering to a healthy lifestyle may be a means to counteract the genetic risk of lethal prostate cancer, a study finds.

Adult men with multiple sclerosis (MS) are more likely to develop erectile dysfunction (ED), indicating that MS is a potential predictor for ED occurrence, suggest the results of a meta-analysis.